Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17123489 | 0.83 | TSHR (0.48) | TSHRLMNAHDAC2 | |
| SCHEMBL15604713 | 0.78 | ALDH1A1 (0.48) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL4254791 | 0.77 | TSHR (0.62) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL17378039 | 0.74 | ALDH1A1 (0.44) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL4263860 | 0.74 | ALDH1A1 (0.48) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL15604714 | 0.74 | TRPA1 (0.48) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL16939931 | 0.73 | TRPA1 (0.42) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL17369686 | 0.73 | PRKCA (0.39) | TRPA1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL8037898 | 0.70 | MAPT (0.38) | ALDH1A1CYP3A4TSHRLMNA | |
| SCHEMBL16722812 | 0.69 | KMT2A (0.46) | ALDH1A1HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023555-B2 | NSAIDs derivatives and uses thereof | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | CYPRUS UNIVERSITY OF TECHNOLOGY (CY) | 2017-06-22 | — | — | US | disclosed |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | TRPA1 84/4885ALDH1A1 363/4885CYP3A4 1736/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | TRPA1 154/4885ALDH1A1 961/4885CYP3A4 1731/4885 |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | PTGES, PTGES3, PTGS1 | TRPA1 19/4885ALDH1A1 383/4885CYP3A4 360/4885 |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | PTGES, PTGES3, PTGS1 | TRPA1 19/4885ALDH1A1 383/4885CYP3A4 360/4885 |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | NOS2, NOS1, HSF1 | TRPA1 911/4885ALDH1A1 3155/4885CYP3A4 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.